Swiss AI Startup Atlast Bio Raises $12.5M to Revolutionize Drug Trials
Swiss AI startup Atlast Bio, founded by former Google employees, secured $12.5 million funding led by Creandum, an early Spotify investor. The company aims to replace costly Phase II drug trials with AI-driven 12-week virtual patient simulations trained on two million human RNA readouts. This approach could reduce costs, speed up trials, and test drugs across multiple diseases simultaneously. Initial trial results are expected within six weeks.
ET Tech··Zurich